Progressive
Care Inc. and Frostime,
LLC Launch Cold
Chain Integrity Pilot Program
MIAMI, FL -- May 6, 2019 -- InvestorsHub NewsWire
-- Progressive
Care Inc. (OTCQB: RXMD), a personalized
healthcare services and technology company, today announced that it
has launched a cold chain integrity pilot program with
Frostime,
LLC
to
ensure
that all medicines are delivered to the patient at
the
prescribed
temperature
range.
The
Cold Chain Integrity Pilot Program will be
one of the first of its kind for last mile pharmaceutical
logistics. The program is designed to allow
pharmacies who do local deliveries to patients at home with the
first ever temperature
controlled device
that tracks the internal temperature throughout
the journey. PharmCo
RX will be the first pharmacy to incorporate Frostime,
LLC's
cooling
technology
(FrostMed)
into
the delivery system which is beneficial for common
cold
chain medications like insulin,
vaccines,
and antibiotics.
Currently,
there is no regulatory
requirement
from Pharmacies to
validate
cold chain temperatures during the delivery process.
From
the time the medicine leaves PharmCo in South Florida and arrives
to the patient, the company
will
be able to monitor and track the medicine's
temperature exposure
on
the
FrostMed
mobile
app,
to
ensure that the medicine and cooler are remaining at a consistent
temperature level.
"Inaccuracies
in medicine temperatures have been a long-time issue in our
industry," said Shital Mars, CEO of Progressive Care Inc. "We are
excited to be the first pharmacy to initiate this program
with Frostime,
LLC's
patented
state
of the art technology and
to develop trust and integrity in the pharmaceutical cold chain
logistics space."
The
Company chose to work with Frostime,
LLC
for
this pilot program for a
number of reasons
including the ease of use, data integrity, cost, logistical support
and technological advancement. Frostime,
LLC's
FrostMed
product
also is environmentally friendly in that it does not use single use
plastics, Styrofoam or other non-durable materials, or toxic
chemicals. The liquid CO2 is captured from various
industrial sources thus
not increasing the CO2 concentration in the atmosphere.
"It
is a privilege for us to partner with such a progressive and
forward
thinking organization
as Progressive
Care Inc,
to
launch our first
project
aimed at pharmacy
last-mile logistics,"
said Rob Saul, CEO of Frostime,
LLC.
"Progressive Care's market will help us validate
our
product in an extreme weather environment and collect data
enabling
us to enhance
our
patented technology.
With over 6,000 deliveries per month, Progressive Care
is
a perfect fit
for
our technology as a validation partner."
FrostMed
was developed
to replace
the current inconvenient, inefficient, expensive and sometimes
dangerous cooling solutions used in the last mile transport of heat
sensitive medicines, blood products,
antibiotics, vaccines, hormones and
specimens.
About
Frostime,
LLC
Founded in
2014, Frostime, LLC has worked tirelessly to create a
portable cooling device that help overcome portable cooling
challenges faced in a number of
different
industries.
With the upcoming official launch, set for Summer
2019, Frostime, LLC. will provide this new
portable cooling solution to clients ranging from military and
medical logistics to the outdoor sportsman.
Frostime,
LLC
https://frostime.com
https://frostmed.com
For
more immediate updates on the company's media coverage, connect
with Progressive Care and PharmCo on social media:
Progressive Care Inc.
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCo, LLC
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx
About Progressive Care Inc.
Progressive
Care Inc. (OTCQB: RXMD), through its
PharmCo, LLC, is a South Florida health services organization and
provider of prescription pharmaceuticals, compounded medications,
provider of tele-pharmacy services, the sale of anti-retroviral
medications, medication therapy management (MTM), the supply of
prescription medications to long-term care facilities, and health
practice risk management.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance, and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target," "intend" and "expect" and similar expressions, as
they relate to Progressive Care Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
Public Relations Contact:
Kathleen
Gonzales, CMW Media
kathleen@cmwmedia.com
www.cmwmedia.com
Investor Relations Contact:
Armen
Karapetyan, Progressive Care
Senior
Advisor Business Development
Armen@progressivecareus.com
www.progressivecareus.com
www.pharmcopharmacy.com